June 7, 2023 4:44pm

What are the probabilities of algorithms and electronic trading making an impact tomorrow, Thursday?

Pre-open Indications: 2 Hits and 1 Miss

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If you want facts to expose share pricing facts to save your portfolio for deliberate decisions, bookmark this site!

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +92.76 points (+0.28%), the S&P closed DOWN -16.28 points (-0.38%) while the Nasdaq closed DOWN -171.52 points (-1.29%)

 

Henry’omics:

We need to more than consider the economic environment rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies.

Indexes were mixed, while I warn that despite the cell and gene therapy sectors five (5) session rally, anticipate an impact from the Fed’s interest rate hikes.

Economic indicators are down 13-months in a row and it’s coming.

Economic Data Docket: The U.S. trade deficit continued to increase in April, but came in slightly below economists’ expectations. The deficit could translate into lower GDP growth for Q2/23.

 

Wednesday (6/7) … RegMed Investors’ (RMi) pre-open: “flashing the cell and gene therapy’s sector, will it pause or continue to race the field. Will electronic trading raid across the tape?” …  https://www.regmedinvestors.com/articles/12991

 

Pre-open Indications: 2 Hit < Blueprint Medicine (BPMC +$2.03), BioLife Solutions (BLFS -$0.47), Sage Therapeutics (SAGE +$2.79)> and 1 Miss < Regenxbio (RGNX +$0.24),   

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Wednesday’s advance/decline line opened negative at 16 up/ 18 down and 1 flat, flipped neutral with 17 up/ 17 down and 1 flat at the mid-day, ending with a positive close of 19/15 and 1 flat

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was down -0.05% and the XBI was up +0.26%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.72 point or -4.89% at 14.01

 

Closing Down (10 of 15):

  • Alnylam Pharmaceuticals (ALNY -$2.79),
  • Ionis Pharmaceuticals (IONS -$2.78 after Tuesday’s +$1.07 and Monday’s +$0.41),
  • CRISPR Therapeutics (CRSP -$1.80 after Tuesday’s +$1.54 and Monday’s -$1.96),
  • Chinook Therapeutics (KDNY -$0.80 after Tuesday’s -$0.33 and Monday’s -$0.11),
  • BioLife Solutions (BLFS -$0.47),
  • Verve Therapeutics (VERV -$0.29 after Tuesday’s +$1.21 and Monday’s +$0.47),
  • Prime Medicine (PRME -$0.26),
  • Intellia Therapeutics (NTLA -$0.16 after Tuesday’s +$2.35 and Monday’s +$0.31),
  • Cellectis SA (CLLS -$0.10),
  • Solid Biosciences (SLDB -$0.10),

Flat (1):

  • Biostage (OTCQB: BSTG)

Closing Up (10 of 19):

  • Sage Therapeutics (SAGE +$2.79 after Tuesday’ +$1.81 and Monday’s +$2.11),
  • Blueprint Medicine (BPMC +$2.03 after Tuesday’ +$1.98 and Monday’s -$2.20),
  • Vericel (VCEL +$0.47 after Tuesday’ +$1.18),
  • AxoGen (AXGN +$0.41)
  • Ultragenyx (RARE +$0.34),
  • Editas Medicine (EDIT +$0.27 after Tuesday’ +$0.81 and Monday’s -$0.23),
  • Regenxbio (RGNX +$0.24 after Tuesday’ +$0.88 after Monday’s -$0.50),
  • Bellicum Pharmaceuticals (BLCM +$0.18),
  • UniQure NV (QURE +$0.11)
  • Compass Therapeutics (CMPX +$0.11)

 

Q2/23 – June

  • Tuesday closed positive with 29 incliners, 6 decliners and 0 flat
  • Wednesday closed positive with 19 incliners, 15 decliners and 1 flat
  • Monday closed positive with 18 incliners, 17 decliners and 0 flat
  • Friday closed positive with 26 incliners, 8 decliners and 1 flat
  • Thursday closed positive with 28 incliners, 7 decliners and 0 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

I STILL believe in defensive moves i.e., changes in share pricing.

The indexes were mostly lower Wednesday, after reversing sharply from morning highs. Investors found a new reason to worry about rate hikes.

And along followed the cell and gene therapy sector initiating a fifth (5th) uplift session?

Although I believe electronic trading and algorithms are watching “our” universe as “pickings” to reap profits.

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

At ANY time, this week, be ready to take partial profits and exit losers.

As I have stated, “The cell and gene therapy sector WILL be experiencing yet another “flight of Icarus” …  since “our” universe have oscillated between gains and losses since the first of 2023!”

Yet, there is VALUE out there however, it’s about playing or betting the timing of the sector. Even as I had stated, “I wouldn’t be buying into this rally … I would be selling into this upside!”

 

The top three (3) performing in the session:

·         Wednesday: Sage Therapeutics (SAGE), Blueprint Medicine (BPMC) and Vericel (VCEL)

·         Tuesday: Blueprint Medicine (BPMC), Intellia Therapeutics (NTLA) and Sage Therapeutics (SAGE) – again

·         Monday: Sage Therapeutics (SAGE), Prime Medicine (PRME) and Ionis Pharmaceuticals (IONS)

While The worst three (3) in the session:

·         Wednesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and CRISPR Therapeutics (CRSP)

·         Tuesday: Chinook Therapeutics (KDNY), MiMedx (MDXG) and Biostage (OTCQB: BSTG)

·         Monday: Blueprint Medicine (BPMC), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) – again

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

Check your portfolio reports: Vanguard Group was fined and censured by the Financial Industry Regulatory Authority (FINRA) for errors appearing in about 8.5 million customer account statements.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

Biostage (OTCQB: BSTG) … so many issues from the past as many of those “miscreant management” members are still employed!

Wednesday closed FLAT with 46 shares traded after Tuesday closed down -$0.06 with 1,100 shares traded, Monday closed down -$0.33 with 500 shares traded, Friday close up +$0.20 with 1,141 shares traded, Thursday closed down -$0.17 with 1,610 shares traded as last Wednesday closed flat <3-month average =1,484 shares>

·         Biostage (OTCQB: BSTG) finally announced a clinical trial initiation for an IND that was approved on 3/20/2020 – what’s with the time (3 years and 2 months) interval?

·         They wouldn’t have had the IND unless I (Henry) had brought in an FDA specialist and worked so many hours diligently with him and others to NOT be paid!

·         Question: Review the number of shares traded on a weekly and monthly basis … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!

·         Hopefully, BSTG will pay the new CRO having tried to NOT pay the former CRO with them having to squeeze there arrears almost NOT filing the old IND so BSTG had to pay-up after I had worked out the pay plan!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.